AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$HAE

Haemonetics (HAE) Q2 2027 Earnings Call Transcript

Haemonetics reported Q2 2027 earnings, highlighting 6% organic growth in MedSurg and 14% in Apheresis. Key drivers include TEG 6s disposables, VASCADE products, and Persona PLUS adoption. The company raised its fiscal 2027 revenue guidance to 6%-9% organic growth and 8%-11% reported growth, citing strong first-half performance and increased visibility into customer commitments.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Haemonetics (HAE) Q2 2027 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$HAEBullishMed
01

Why it matters

The earnings release delivers fresh financial metrics and an upward revision of FY2027 revenue growth guidance, a material new data point for traders.

02

Market read

Guidance lift may drive short-term price appreciation; sector peers could benefit from positive sentiment.

03

What to watch

Higher operating expenses and margin pressure could offset revenue growth benefits.

Relevance 8/10Novelty 8/10Timing: post-earnings release today

Background

Haemonetics' Q2 earnings call covered organic growth across MedSurg, apheresis, and interventional technologies, and announced new product approvals and expanded regulatory clearances.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics provided Q2 2027 earnings results and raised FY2027 organic revenue growth guidance to 6%-9% (up from 4%-7%).

Expected impact

potential modest upside as investors price in higher revenue growth guidance

Evidence & confidence

Guidance lift is a primary disclosure and materially improves outlook; market typically reacts positively to raised guidance.

Market effects

Sector

Improved outlook for medical device and blood management sector may lift peers.

Regional

U.S. healthcare equipment segment could see modest buying pressure.

Global

Limited to investors focused on U.S. med‑tech equities.

Counterpoint

What could challenge this read

Guidance raise may already be priced in; execution risk could limit upside.

Key entities

  • Company
    Haemonetics

    Medical device maker reporting Q2 2027 results and guidance.

Read at source← All news

StoryHaemonetics beats fiscal Q2 estimates and raises full-year revenue outlook

Also covered by

4 outlets

Related articles

$HAEMedAI 8/10

Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded

Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.

finance.yahoo.com
$HAEHighAI 8/10

Haemonetics Corporation Q2 2027 Earnings Call Summary

Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.

finance.yahoo.com
$HAEMed

Mizuho raises Haemonetics stock price target on plasma strength

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

investing.com
$HAEHighAI 8/10

BTIG raises Haemonetics stock price target to $142 on earnings beat

BTIG raised its price target on Haemonetics (HAE) to $142 from $130, maintaining a Buy rating. HAE's Q2 2027 revenue was $357.8M, up 9.3% YoY, beating estimates. Adjusted EPS was $1.35, exceeding expectations. All segments performed well, with Apheresis revenue at $204.8M. Adjusted gross margin increased to 61.9%. HAE raised fiscal 2027 revenue guidance but reduced adjusted EBIT margin expansion outlook.

investing.com